Related references
Note: Only part of the references are listed.Circulating cell free DNA: Preanalytical considerations
Safia El Messaoudi et al.
CLINICA CHIMICA ACTA (2013)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Mi-Jung Kim et al.
BMC CANCER (2012)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Karen-Lise Garm Spindler et al.
CLINICAL CANCER RESEARCH (2012)
The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients
Florent Mouliere et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
Florence Boissiere-Michot et al.
MODERN PATHOLOGY (2012)
KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab
H. Bando et al.
BRITISH JOURNAL OF CANCER (2011)
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
R. Mead et al.
BRITISH JOURNAL OF CANCER (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
Colorectal cancer molecular biology moves into clinical practice
Colin C. Pritchard et al.
GUT (2011)
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
Satu Oltedal et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
Jerome Solassol et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Florent Mouliere et al.
PLOS ONE (2011)
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pedro Pinto et al.
CANCER GENETICS (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer
Benoit Lefebure et al.
ANNALS OF SURGERY (2010)
The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR
Takashi Kobunai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
Ruth E. Board et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients
N. P. West et al.
BRITISH JOURNAL OF CANCER (2010)
KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics - Comparison of Methods and Impact of Histology
Wilko Weichert et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
Alain R. Thierry et al.
NUCLEIC ACIDS RESEARCH (2010)
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
Li-Chen Yen et al.
CLINICAL CANCER RESEARCH (2009)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Junichi Soh et al.
PLOS ONE (2009)
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients
Frank Diehl et al.
GASTROENTEROLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
BM Ryan et al.
GUT (2003)
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis
T Lecomte et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
